NovaBridge to Present at Two Investor Conferences
NovaBridge Biosciences will present at the Jefferies conference in London and hold a fireside chat at the Evercore Healthcare Conference later this month.
Updated on Nov. 9, 2026 in Biotech
NovaBridge Biosciences, a Nasdaq-listed company (NBP) headquartered in Rockville, Md., will take part in two upcoming investor conferences. The company's portfolio is led by givastomig, a Claudin 18.2 × 4-1BB bispecific antibody under development for gastrointestinal malignancies.
Why it matters
The appearances give investors and analysts a scheduled opportunity to hear from company leadership about NovaBridge's pipeline and operations. The company's lead candidate targets gastrointestinal cancers, a therapeutic area where investor interest in bispecific antibodies remains active.
The company's lead asset, givastomig, is a Claudin 18.2 × 4-1BB bispecific antibody, and webcasts of both presentations will be accessible on the NovaBridge website for 90 days. The announcement provides no further technical specifications for the candidate.
The players
NovaBridge Biosciences
A Nasdaq-listed biosciences company headquartered in Rockville, Maryland, whose pipeline is led by givastomig and which holds a majority stake in the ophthalmology subsidiary Visara.
Srishti Gupta
The Chief Executive Officer of NovaBridge Biosciences, who leads the company's strategic and clinical direction.
The details
NovaBridge Biosciences will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, and participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Monday, November 30, 2026. Both appearances will include one-on-one meetings with investors.
Timeline
Monday, November 16, 2026: Jefferies Global Healthcare Conference presentation in London.
Monday, November 30, 2026: Evercore Healthcare Conference fireside chat.
Roadmap
Claudin 18.2 has drawn sustained drug-development interest as a target in gastric and gastroesophageal cancers, and NovaBridge's givastomig is one of several bispecific candidates pursuing that target. The company's investor outreach places its pipeline within that competitive field.
Investors who want direct access to NovaBridge management can attend the scheduled presentations or request one-on-one meetings. Those unable to attend can view the webcasts on the company website for 90 days after the events.
The takeaway
Scheduled investor conferences give shareholders and prospective investors a defined window to ask management about the company's pipeline. Reviewing the webcasts afterward can help readers track any updates NovaBridge provides.
What happens next
NovaBridge Biosciences will present at the Jefferies Global Healthcare Conference in London on November 16, 2026, and hold a fireside chat at the Evercore Healthcare Conference on November 30, 2026.
Further reading
For more on the companies shaping this field, explore Biotech coverage.
